BTIG analyst Sam Eiber has initiated coverage on BrainsWay with a Buy rating and announced a price target of $18. The company is listed on NASDAQ under the ticker BWAY. The rating initiation reflects a positive outlook on the stock based on the analyst's assessment.

Analyst Details

Sam Eiber, an analyst at BTIG, provided the coverage initiation. The Buy rating suggests that the stock is expected to outperform the market.

Price Target

The price target set by BTIG is $18. This target indicates the analyst's projected value for the stock over a specified period.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) has invested $500,000 for a minority position in Sound Minds Behavioral, a growth-oriented outpatient behavioral health platform. The investment is structured as a preferred, annually compounding security aimed at expanding access to interventional psychiatry solutions. This strategic equity financing round supports Sound Minds Behavioral's operations across Connecticut, Pennsylvania, New Jersey, and New York.

The agreement facilitates the partner's expansion through growth capital while allowing BrainsWay to maintain its focus on scientific and clinical advancement. Hadar Levy, Chief Executive Officer of BrainsWay, emphasized that the minority stake approach enables the company to deliver best-in-class support to its customers. The partnership is expected to enhance the cutting-edge mental health treatments provided by Sound Minds Behavioral.

Sound Minds Behavioral offers therapy, medication management, PHP/IOP, and interventional psychiatry services. Jordan Klear, Chairman and Chief Executive Officer of Sound Minds Behavioral, stated that the partnership will support continued growth and expand access to evidence-based care. The organization focuses on scalable clinical operations and clinical partnerships.

The investment transaction was made with CM Counsel Management LLC, doing business as Sound Minds Behavioral. Advocates Ami Hordes and Sarit Molcho of S. Friedman, Abramson & Co. Law Offices served as lead counsel for BrainsWay on the transaction.

Key Transaction Details

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company's proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology has obtained three FDA-cleared indications. These include major depressive disorder, obsessive-compulsive disorder, and smoking addiction.